Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Sitravatinib + tislelizumab in advanced BTC after systemic treatment failure: Phase II study

Jeesun Yoon, MD, Seoul National University, Seoul, South Korea, presented findings from an open-label, Phase II trial (NCT04727996) investigating the efficacy of sitravatinib and tislelizumab combination therapy for second-line advanced biliary tract cancer (BTC). Given the established standard of care using immune checkpoint inhibitors (ICI) in combination with cytotoxic chemotherapy in first-line BTC treatment, there’s a pressing need for novel therapies in later lines. The study enrolled 43 patients, including those who had previously received ICI. Results showed a disease control rate of 65.1% and an overall response rate of 20.5%, with a median progression-free survival of 4.93 months and a median overall survival of 10.3 months. Adverse events were predominantly related to sitravatinib, with manageable immune-related adverse events. Importantly, exploratory analysis suggested that patients with homologous recombination deficiency (HRD) may benefit more from this treatment, indicating the potential for biomarker-driven patient selection. The study underscores the promising efficacy and safety profile of sitravatinib/tislelizumab combination therapy in second-line advanced BTC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.